Thomas R Magee1, Michael G Ross2, Lauren Wedekind3, Mina Desai2, Siri Kjos4, Louiza Belkacemi5. 1. Department of Obstetrics and Gynecology, Perinatal Research Laboratories, David Geffen School of Medicine at University of California in Los Angeles, Los Angeles, CA, USA; Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA, USA; Department of Health and Life Sciences at Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA. 2. Department of Obstetrics and Gynecology, Perinatal Research Laboratories, David Geffen School of Medicine at University of California in Los Angeles, Los Angeles, CA, USA; Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA, USA. 3. Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA, USA. 4. Department of Obstetrics and Gynecology, Perinatal Research Laboratories, David Geffen School of Medicine at University of California in Los Angeles, Los Angeles, CA, USA. 5. Department of Obstetrics and Gynecology, Perinatal Research Laboratories, David Geffen School of Medicine at University of California in Los Angeles, Los Angeles, CA, USA; Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA, USA. Electronic address: lbelkacemi1@gmail.com.
Abstract
AIM: Increased placental growth secondary to reduced apoptosis may contribute to the development of macrosomia in GDM pregnancies. We hypothesize that reduced apoptosis in GDM placentas is caused by dysregulation of apoptosis related genes from death receptors or mitochondrial pathway or both to enhance placental growth in GDM pregnancies. METHODS: Newborn and placental weights from women with no pregnancy complications (controls; N=5), or with GDM (N=5) were recorded. Placental villi from both groups were either fixed for TUNEL assay, or snap frozen for gene expression analysis by apoptosis PCR microarrays and qPCR. RESULTS: Maternal, placental and newborn weights were significantly higher in the GDM group vs. Controls. Apoptotic index of placentas from the GDM group was markedly lower than the Controls. At a significant threshold of 1.5, seven genes (BCL10, BIRC6, BIRC7, CASP5, CASP8P2, CFLAR, and FAS) were down regulated, and 13 genes (BCL2, BCL2L1, BCL2L11, CASP4, DAPK1, IκBκE, MCL1, NFκBIZ, NOD1, PEA15, TNF, TNFRSF25, and XIAP) were unregulated in the GDM placentas. qPCR confirmed the consistency of the PCR microarray. Using Western blotting we found significantly decreased placental pro-apoptotic FAS receptor and FAS ligand (FASL), and increased mitochondrial anti-apoptotic BCL2 post GDM insult. Notably, caspase-3, which plays a central role in the execution-phase of apoptosis, and its substrate poly (ADP-ribose) polymerase (PARP) were significantly down regulated in GDM placentas, as compared to non-diabetic Control placentas. CONCLUSION: Maternal GDM results in heavier placentas with aberrant placental apoptotic and inflammatory gene expression that may account, at least partially, for macrosomia in newborns.
AIM: Increased placental growth secondary to reduced apoptosis may contribute to the development of macrosomia in GDM pregnancies. We hypothesize that reduced apoptosis in GDM placentas is caused by dysregulation of apoptosis related genes from death receptors or mitochondrial pathway or both to enhance placental growth in GDM pregnancies. METHODS: Newborn and placental weights from women with no pregnancy complications (controls; N=5), or with GDM (N=5) were recorded. Placental villi from both groups were either fixed for TUNEL assay, or snap frozen for gene expression analysis by apoptosis PCR microarrays and qPCR. RESULTS: Maternal, placental and newborn weights were significantly higher in the GDM group vs. Controls. Apoptotic index of placentas from the GDM group was markedly lower than the Controls. At a significant threshold of 1.5, seven genes (BCL10, BIRC6, BIRC7, CASP5, CASP8P2, CFLAR, and FAS) were down regulated, and 13 genes (BCL2, BCL2L1, BCL2L11, CASP4, DAPK1, IκBκE, MCL1, NFκBIZ, NOD1, PEA15, TNF, TNFRSF25, and XIAP) were unregulated in the GDM placentas. qPCR confirmed the consistency of the PCR microarray. Using Western blotting we found significantly decreased placental pro-apoptotic FAS receptor and FAS ligand (FASL), and increased mitochondrial anti-apoptotic BCL2 post GDM insult. Notably, caspase-3, which plays a central role in the execution-phase of apoptosis, and its substrate poly (ADP-ribose) polymerase (PARP) were significantly down regulated in GDM placentas, as compared to non-diabetic Control placentas. CONCLUSION: Maternal GDM results in heavier placentas with aberrant placental apoptotic and inflammatory gene expression that may account, at least partially, for macrosomia in newborns.
Authors: Gabriel Sollberger; Gerhard E Strittmatter; Magdalena Kistowska; Lars E French; Hans-Dietmar Beer Journal: J Immunol Date: 2012-01-13 Impact factor: 5.422
Authors: Caroline A Crowther; Janet E Hiller; John R Moss; Andrew J McPhee; William S Jeffries; Jeffrey S Robinson Journal: N Engl J Med Date: 2005-06-12 Impact factor: 91.245
Authors: M V C Rudge; D C Damasceno; G T Volpato; F C G Almeida; I M P Calderon; I P Lemonica Journal: Braz J Med Biol Res Date: 2007-08 Impact factor: 2.590
Authors: D Szukiewicz; Grzegorz Szewczyk; Michal Pyzlak; Aleksandra Stangret; Michal Bachanek; Seweryn Trojanowski; Habib Alkhalayla; Jaroslaw Wejman Journal: Inflammation Date: 2018-12 Impact factor: 4.092
Authors: Paula Krakowiak; Cheryl K Walker; Daniel Tancredi; Irva Hertz-Picciotto; Judy Van de Water Journal: Autism Res Date: 2016-06-17 Impact factor: 5.216
Authors: Dariusz Szukiewicz; Michal Pyzlak; Grzegorz Szewczyk; Aleksandra Stangret; Seweryn Trojanowski; Michal Bachanek; Wojciech Braksator; Jaroslaw Wejman Journal: Mediators Inflamm Date: 2017-06-01 Impact factor: 4.711